MET and alveolar rhabdomyosarcoma: Approximately 80% of ARMS tumors are characterized with the translocations or expression of the PAX3/7–FOXO1 fusion transcript, resulting in overexpression of receptor tyrosine kinases such as fibroblast growth factor receptor 4 (FGFR4), hepatocyte growth factor receptor (HGFR, also named MET), and insulin-like growth factor 1 receptor (IGF-1R) [1,2].